| Literature DB >> 32739140 |
Emanuele Gammeri1, Giulia Maria Cillo2, Romeshan Sunthareswaran2, Tania Magro2.
Abstract
BACKGROUND: Resumption of elective surgery during the current coronavirus disease 2019 pandemic crisis has been debated widely and largely discouraged. The aim of this prospective cohort study was to assess the feasibility of resuming elective operations during the current and possible future peaks of this coronavirus disease 2019 pandemic.Entities:
Mesh:
Year: 2020 PMID: 32739140 PMCID: PMC7362797 DOI: 10.1016/j.surg.2020.07.003
Source DB: PubMed Journal: Surgery ISSN: 0039-6060 Impact factor: 3.982
Fig 1Risk assessment tool during COVID-19 pandemic for non-urgent surgery.
General demographic data
| No (%) | |
|---|---|
| Variable | Total ( |
| Age, y | |
| Mean (SD) | 61.9 (17.2) |
| Age group | |
| ≤45 | 54 (17.5) |
| 46–64 | 106 (34.3) |
| 65–74 | 66 (21.4) |
| 75–84 | 54 (17.45) |
| ≥85 | 29 (9.38) |
| Sex | |
| Female | 167 (54.0) |
| Male | 142 (46.0) |
| ASA classification | |
| I | 98 (31.7) |
| II | 181 (58.6) |
| III | 29 (9.4) |
| IV | 1 |
| Temperature on admission | |
| ≤37.1 | 292 (94.5) |
| 37.2–37.8 | 17 (5.5) |
| ≥37.9 | 0 |
| Comorbidities | |
| Asthma | 22 (7.1) |
| Atrial fibrillation | 26 (8.4) |
| Cerebral vascular disease | 21 (6.8) |
| CKD | 12 (3.9) |
| COPD | 12 (3.9) |
| Hypertension | 88 (28.5) |
| Ischemic heart disease | 20 (6.5) |
| Type 2 diabetes mellitus | 15 (4.9) |
| BMI | |
| Mean (SD) | 26.82 (4.9) |
| Not recorded | 5 (1.1) |
| <18.5 | 3 (1) |
| 18.5–24.9 | 108 (35.0) |
| 25.0–34.9 | 171 (55.3) |
| 35–44.9 | 21 (7.0) |
| >45 | 1 |
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
Description of operative details
| No (%) | |
|---|---|
| Surgical Specialty | Total ( |
| Breast surgery | 45 (14.56) |
| Axillary node dissection | 2 |
| Deconstruction of DIEP of breast ± reconstruction | 2 |
| Mastectomy & SLNB ± ANC | 8 |
| Re-excision breast margin | 4 |
| Simple mastectomy | 4 |
| WLE ± SLNB | 6 |
| WG-WLE ± SLNB | 16 |
| WLE & ANC | 3 |
| ENT surgery | 2 (0.64) |
| Insertion of grommets | 1 |
| Pan-endoscopy | 1 |
| General surgery | 22 (7.11) |
| Femoral hernia repair | 2 |
| Laparoscopic cholecystectomy | 10 |
| Open inguinal hernia repair | 4 |
| Paraumbilical hernia repair | 1 |
| Unilateral thyroid lobectomy | 5 |
| Gynecology | 13 (4.20) |
| Hysteroscopy, uterine biopsy ± coil insertion | 9 |
| Laparoscopic ovarian cystectomy | 1 |
| LLETZ ± diathermy of vaginal warts | 2 |
| WLE of vulva | 1 |
| Orthopedics | 37 (11.97) |
| Ankle syndesmosis reconstruction | 1 |
| Anterior cervical decompression and fusion | 2 |
| Arthroscopy of the knee | 1 |
| Carpal tunnel decompression | 7 |
| Cervical laminectomy/laminoplasty | 5 |
| Lumbar spine decompression | 1 |
| MUA, closed reduction ± K wire fixation | 5 |
| ORIF (clavicle, malleolus, radius, Lis-Franc injury) | 9 |
| Tendons repairs (biceps, quadriceps, great toe) | 5 |
| Total shoulder replacement | 1 |
| Pain management | 26 (8.41) |
| PRF of major nerve trunk | 15 |
| Facet joint injection ± denervation | 10 |
| Neurostimulation of peripheral nerve | 1 |
| Plastic surgery | 122 (39.48) |
| Excision of cancerous skin lesion + FTSG | 13 |
| Excision biopsy of skin lesion ± local flap | 13 |
| Excision of cancerous skin lesion (MM, BCC, SCC) | 64 |
| Axillary regional lymphadenectomy | 2 |
| Shave biopsy of skin lesion | 1 |
| Ulnar nerve decompression | 1 |
| WLE excision of cancerous lesion (MM, BCC, SCC) | 28 |
| Urology | 42 (13.59) |
| Cystoscopy + biopsy | 12 |
| Cystoscopy + biopsy + right ureteroscopy | 1 |
| Cystoscopy + insertion of SPC + urethral dilatation | 1 |
| Orchidectomy ± open inguinal hernia repair | 3 |
| Rigid cystoscopy ± change of stent | 4 |
| Rigid ureteroscopy & ureteric stent removal | 4 |
| Rigid ureteroscopy and fragmentation of ureteric stone ± stent insertion | 5 |
| TURBT | 10 |
| TURP | 2 |
| Grade of operation | |
| Minor | 28 (9.0) |
| Intermediate | 281 (91.0) |
| Type of anesthesia | |
| General | 158 (51.1) |
| Local | 151 (48.9) |
| Grade of operating surgeon | |
| Consultant | 249 (80.6) |
| Associate specialist | 18 (5.8) |
| Registrar | 42 (13.6) |
ANC, axillary node clearance; BCC, basal cell carcinoma; DIEP, deep inferior epigastric perforator; ENT, ear, nose and throat; FTSG, full-thickness skin grafting; LLETZ, large loop excision of the transformation zone; MM, malignant melanoma; MUA, manipulation under anesthesia; ORIF, open reduction and internal fixation; PRF, pulsed radiofrequency; SCC, squamous cell carcinoma; SLNB, sentinel lymph node biopsy; TURBT, transurethral resection of bladder tumor; TURP, transurethral resection of the prostate; WG, wire guided; WLE, wide local excision.
Operative outcome, readmission, and complications
| No (%) | |
|---|---|
| Duration of stay | |
| <23 h | 306 |
| 24–72 h | 2 |
| >72 h | 1 |
| Complications | 27 (8.7) |
| Abscess | 1 |
| Epidural hematoma | 1 |
| Hematoma | 1 |
| CBD retained stone | 1 |
| Breast seroma | 8 |
| Urinary retention | 2 |
| Urinary tract infection | 2 |
| Wound dehiscence | 1 |
| Wound infection | 10 |
| Hospital Readmission | |
| None | 0 |
| ITU admissions | |
| None | 0 |
| Pulmonary complications | |
| No | 309 (100) |
| Pneumonia | 0 |
| ARDS | 0 |
| Deaths | |
| None | 0 |
| 30-d mortality | |
| None | 0 |
| Clavien-Dindo classification | |
| I | 13 (4.2) |
| II | 12 (3.9) |
| IIIA–IIIB | 2 |
| IVA–IVB | 0 |
| V | 0 |
| COVID-19 PCR swab | |
| Preoperatively | 104 (33.7) |
| Postoperatively | 1 |
ARDS, acute respiratory distress syndrome; CBD, common bile duct; ITU, intensive therapy unit; PCR, polymerase chain reaction.